Multidisciplinary care of gastrointestinal stromal tumour: A review and a proposal for a pre-treatment classification

F. C M Cananzi, I. Judson, B. Lorenzi, C. Benson, S. Mudan

Research output: Contribution to journalArticlepeer-review


The introduction of receptor tyrosine kinase inhibitors (TKIs) has revolutionized the management of gastrointestinal stromal tumour (GIST). Strong evidence supports the use of imatinib as first-line treatment in metastatic or unresectable tumours and its efficacy in the post-operative adjuvant setting has been confirmed by phase III trials. There are a number of reports concerning the administration of imatinib in the pre-operative setting, however, the heterogeneity of the terminology used and the indications for pre-operative treatment make it difficult to determine the true value of pre-operative imatinib. Larger studies, or a phase III trial could be helpful but patient accrual and standardization of care could be difficult. We propose a pre-treatment classification of GIST in order to facilitate the comparison and collection of data from different institutions, and overcome the difficulties related to accrual. Moreover, in the current era of multidisciplinary treatment of GIST, an appropriate classification is mandatory to properly design clinical trials and plan stage-adapted treatment.

Original languageEnglish
Pages (from-to)1171-1178
Number of pages8
JournalEuropean Journal of Surgical Oncology
Issue number11
Publication statusPublished - Nov 2013


  • Classification
  • GIST
  • Imatinib
  • Pre-operative therapy
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Multidisciplinary care of gastrointestinal stromal tumour: A review and a proposal for a pre-treatment classification'. Together they form a unique fingerprint.

Cite this